Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
316 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01685060 | LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib | completed | Phase 2 | 140 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 19, 2017 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 |
| clinicaltrials |
| NCT03146377 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 32 | The University of Hong KongOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT01249547 | Nasopharyngeal Carcinoma (NPC) Axitinib | completed | Phase 2 | 37 | Chinese University of Hong KongOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 225 | GlaxoSmithKlineINDUSTRY | 8 | Mar 27, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT00089999 | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | completed | Phase 2 | 138 | GlaxoSmithKlineINDUSTRY | 11 | Feb 28, 2017 | clinicaltrials |
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 7, 2017 | clinicaltrials |
| NCT01370070 | MK-2206 in Recurrent Nasopharyngeal Carcinoma(MC1079) | completed | Phase 2 | 12 | Chinese University of Hong KongOTHER | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT01437566 | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy | completed | Phase 2 | 318 | Genentech, Inc.INDUSTRY | 23 | Nov 2, 2016 | clinicaltrials |
| NCT00813605 | QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | completed | Phase 2 | 155 | NantCell, Inc.INDUSTRY | 10 | Oct 27, 2016 | clinicaltrials |
| NCT01251458 | Hepatocellular Carcinoma (HCC)_Torisel_ | completed | Phase 1 / Phase 2 | 46 | Chinese University of Hong KongOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 1, 2016 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | completed | Phase 2 | 26 | Boehringer IngelheimINDUSTRY | 7 | Jul 19, 2016 | clinicaltrials |
| NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 207 | Hoffmann-La RocheINDUSTRY | 19 | Jun 17, 2016 | clinicaltrials |
| NCT01585987 | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | completed | Phase 2 | 143 | Bristol-Myers SquibbINDUSTRY | 12 | May 17, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT02608073 | A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 5 | Mar 2, 2016 | clinicaltrials |
| NCT02625168 | Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC | completed | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00791778 | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 246 | BayerINDUSTRY | 14 | Sep 28, 2015 | clinicaltrials |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects | completed | Phase 2 | 67 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 13 | Sep 2, 2015 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT00226811 | An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy | completed | Phase 2 | 78 | PfizerINDUSTRY | 7 | Mar 30, 2015 | clinicaltrials |
| NCT01227928 | Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | completed | Phase 2 | 145 | GlaxoSmithKlineINDUSTRY | 4 | Mar 3, 2015 | clinicaltrials |
| NCT00652366 | A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 467 | Hoffmann-La RocheINDUSTRY | 23 | Feb 11, 2015 | clinicaltrials |
| NCT01998919 | A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer. | completed | Phase 2 | 154 | Hoffmann-La RocheINDUSTRY | 8 | Jan 13, 2015 | clinicaltrials |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 96 | BayerINDUSTRY | 6 | Oct 31, 2014 | clinicaltrials |
| NCT00700180 | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 2 | 303 | Hoffmann-La RocheINDUSTRY | 16 | Sep 25, 2014 | clinicaltrials |
| NCT00576199 | A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00439517 | Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.(FUTURE) | completed | Phase 2 | 302 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 14 | Jun 27, 2014 | clinicaltrials |
| NCT02013830 | A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer | completed | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 4 | Jun 6, 2014 | clinicaltrials |
| NCT00003044 | Chemotherapy in Treating Patients With Liver Cancer | unknown | Phase 2 | 55 | Matrix PharmaceuticalINDUSTRY | 2 | Dec 19, 2013 | clinicaltrials |
| NCT01204177 | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.(BASIL) | completed | Phase 2 | 70 | BayerINDUSTRY | 4 | Sep 6, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00062257 | Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer | completed | Phase 2 | — | Cancer Therapeutics Research GroupOTHER | 4 | May 15, 2013 | clinicaltrials |
| NCT00077402 | Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 2 | 50 | Cancer Therapeutics Research GroupOTHER | 3 | May 15, 2013 | clinicaltrials |
| NCT00077415 | 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 31 | Cancer Therapeutics Research GroupOTHER | 4 | May 15, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00550173 | A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 247 | Eli Lilly and CompanyINDUSTRY | 7 | Feb 13, 2013 | clinicaltrials |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | completed | Phase 2 | 163 | GlaxoSmithKlineINDUSTRY | 28 | Feb 4, 2013 | clinicaltrials |
| NCT00319254 | Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer | completed | Phase 2 | 75 | PfizerINDUSTRY | 8 | Jan 31, 2013 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials